Lipoprotein-associated phospholipase A2 antibody compositions and methods of use
AssigneediaDexus, Inc.
InventorsPaul Levi Miller, Laura Corral
Life of this patent
Estimating the term…
Abstract
The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
Claims13
An isolated antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment binds to Lp-PLA2 and comprises:
- a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 2, 12, and 22;
- and
- a heavy chain variable region.
An isolated antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment binds to Lp-PLA2 and comprises:
- a light chain variable region;
- and
- a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 7, 17, and 27.
An isolated monoclonal antibody or antigen binding fragment thereof that binds to Lp-PLA2, the antibody or antigen binding fragment comprising:
- a light chain variable region comprising CDR1, CDR2 and CDR3 sequences;
- and a heavy chain variable region comprising CDR1, CDR2, CDR3 sequences, wherein:
- (a) the light chain variable region comprises:
- a light chain CDR1 having an amino acid sequence of SEQ ID NO:
- 3,
- a light chain CDR2 having an amino acid sequence of SEQ ID NO:
- 4,
- a light chain CDR3 having an amino acid sequence of SEQ ID NO:
- 5;
- and
- (b) the heavy chain variable region comprises:
- a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:
- 8,
- a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:
- 9,
- a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:
- 10.
An isolated monoclonal antibody or antigen binding fragment thereof that binds to Lp-PLA2, the antibody or antigen binding fragment comprising:
- a light chain variable region comprising CDR1, CDR2 and CDR3 sequences;
- and a heavy chain variable region comprising CDR1, CDR2, CDR3 sequences, wherein:
- (a) the light chain variable region comprises:
- a light chain CDR1 having an amino acid sequence of SEQ ID NO:
- 13,
- a light chain CDR2 having an amino acid sequence of SEQ ID NO:
- 14,
- a light chain CDR3 having an amino acid sequence of SEQ ID NO:
- 15;
- and
- (b) the heavy chain variable region comprises:
- a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:
- 18,
- a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:
- 19,
- a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:
- 20.
An isolated monoclonal antibody or antigen binding fragment thereof that binds to Lp-PLA2, the antibody or antigen binding fragment comprising:
- a light chain variable region comprising CDR1, CDR2 and CDR3 sequences;
- and a heavy chain variable region comprising CDR1, CDR2, CDR3 sequences, wherein:
- (a) the light chain variable region comprises:
- a light chain CDR1 having an amino acid sequence of SEQ ID NO:
- 23,
- a light chain CDR2 having an amino acid sequence of SEQ ID NO:
- 24,
- a light chain CDR3 having an amino acid sequence of SEQ ID NO:
- 25;
- and
- (b) the heavy chain variable region comprises:
- a heavy chain CDR1 having an amino acid sequence of SEQ ID NO:
- 28,
- a heavy chain CDR2 having an amino acid sequence of SEQ ID NO:
- 29,
- a heavy chain CDR3 having an amino acid sequence of SEQ ID NO:
- 30.
Dependencies are inferred from the claim text.